European Pharmaceutical Review

JUNE 28, 2022

billion by 2026, achieving a compound annual growth rate (CAGR) of 13.2 Advancements are underway in terms of product developments and innovations, with significant emphasis being placed on optimising and streamlining existing methods. percent CAGR between 2022 and 2026.

Dosage 111

Dosage Compounding Drug Development 111

Express Pharma

MAY 10, 2023

Work is set to begin this year, with full operations provisionally planned for late 2026. The post Sandoz partners with Just–Evotec Biologics to develop and manufacture multiple biosimilars appeared first on Express Pharma.

Biosimilars 97

Biosimilars Drug Development 97

European Pharmaceutical Review

DECEMBER 22, 2023

KarXT’s novel mechanism has resulted in a transformational profile in schizophrenia, with compelling efficacy and a differentiated safety profile,” said Samit Hirawat, MD, Executive Vice President, Chief Medical Officer, Drug Development of Bristol Myers Squibb.

Drug Development 98

Drug Development 98

Pharma Mirror

JANUARY 24, 2023

Science-based innovation for manufacturing high quality cells challenges dogma and terminology Cell and gene therapies are dominating the world of drug development. billion by 2026, up from $186 billion in 2019 according to the Evaluate Pharma report.

Drug Development 52

Drug Development Diabetes 52

pharmaphorum

APRIL 4, 2022

Tsai’s dual role as CMO and had of global drug development is being filled by Shreeram Aradhye, a Novartis veteran who will return to the company on 16 May after a few years at biotechs Dicerna Pharma – just acquired by Novo Nordisk for $3.3 billion – as well as Axcella health.

Drug Development 59

Drug Development 59

Safe Biologics

OCTOBER 10, 2023

A Better Reform: Ensuring Savings Are Passed Onto Patients While price-setting proponents say beneficiaries will start to see lower drug prices beginning in 2026, there’s no evidence that this is true, and there are better ways to lower out-of-pocket costs- and much faster, Reilly explains. – View clip.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

pharmaphorum

MARCH 14, 2022

Million by 2026, growing at a CAGR of 4.40 % from 2019 to 2026. Analgesic pre-clinical development. Drug development. Exploratory development. The global Postoperative Pain Therapeutics Market was valued at USD 11.26 Million in 2018 and is projected to reach USD 15.87 Anaesthesia and Pain Management. •

Compounding 52

Compounding Drug Development 52

European Pharmaceutical Review

SEPTEMBER 15, 2023

EPR are attending the event – let us know so our team can organise an interview with you or your company, or provide more information on opportunities such as sponsorship.

Packaging 119

Packaging Drug Development 119

European Pharmaceutical Review

DECEMBER 30, 2023

There is also a high unmet need in the CNS space, and there have been a number positive results with respect to drug development; as a result, we expect this to be a therapeutic area with dealmaking potential,” Baral continues. We expect the growth gap to increase to $120 billion across the top 25 biopharma companies by 2028.

Drug Development 105

Drug Development 105

pharmaphorum

JUNE 2, 2022

Evaluate Pharma’s recent Orphan Drug Report subtitled its overview of the market ‘Niche no longer.’ This is based on the relative success orphan drugs have achieved, in terms of the number of approvals and the sales figures achieved for this area.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 52

pharmaphorum

JULY 26, 2022

NewAmsterdam Pharma has charted out a route to a Nasdaq listing by merging with black cheque company Frazier Lifesciences in a deal that will provide additional cash for its main drug candidate – oral CETP inhibitor obicetrapib. Remember CETP?

Drug Development 52

Drug Development 52

Pharmaceutical Technology

JANUARY 31, 2023

The US omnibus bill passed in late December 2022 will give the agency greater powers to regulate accelerated approval drugs, while the Inflation Reduction Act’s lowering of drug prices will create an uncertain environment for drug developers, he said. That leaves three years for pharma companies to prepare.

Drug Pricing 52

Drug Pricing Biosimilars Drug Development 52

pharmaphorum

DECEMBER 14, 2022

Pretzel Therapeutics, headquartered in Boston, aims to develop genetic therapies that fix many of these disorders, and Angelini Ventures supports this work through its participation in the company’s Series A round. By 2026, Argobio Studio SAS will create and launch five or more biotech companies.

Drug Development 105

Drug Development 105

European Pharmaceutical Review

FEBRUARY 7, 2023

of the MDR and Article 110.4 of the IVDR for medical devices and in vitro diagnostic medical devices (IVDs).

Packaging 117

Packaging Drug Development 117

Putting Patients First Blog

APRIL 14, 2023

Driven by the work of the Food and Drug Administration on patient-focused drug development (PFDD), many companies in the biopharmaceutical community have devoted significant resources to better understand patient populations and are working to bring to market products that best suit their needs. Sincerely, Randall L.

Drug Pricing 40

Drug Pricing Drug Development Documentation Communication 40

Viseven

SEPTEMBER 18, 2024

When COVID hit, the urgent need to accelerate drug development meant shrinking timelines from years to months, with no room for compromises on quality. This innovative approach has brought more than 40 successful drug discovery projects to AstraZeneca. By the end of 2026, the company will be able to analyze two million genomes.

Communication 52

Communication Vaccines Pharmaceutical Companies Pharmaceutical Companies 52

PharmaShots

FEBRUARY 21, 2023

threshold by 2026. This year, Novartis has secured the top position with a market cap of $207.65B, followed by Bayer and Lantheus Medical Imaging PharmaShots has compiled a list of the Top 20 Radiopharma Companies developing products as a treatment option, ranked based on their market cap.

Dosage 56

Dosage Labelling Immunity Immunization 56

Putting Patients First Blog

SEPTEMBER 30, 2024

The goal of the rare pediatric disease PRV program is to incentivize drug development for rare pediatric diseases. billion through fiscal year 2026. Extension of Priority Review Vouchers FDA Priority Review Vouchers (PRVs) for rare pediatric diseases were extended through December 20, 2024.The The CR also provides $27.1

Department of Veterans Affairs 98

Department of Veterans Affairs Packaging Drug Development 98

Safe Biologics

SEPTEMBER 11, 2023

A Better Reform: Ensuring Savings Are Passed Onto Patients While price-setting proponents say beneficiaries will start to see lower drug prices beginning in 2026, there’s no evidence that this is true, and there are better ways to lower out-of-pocket costs- and much faster, Reilly explains.

Drug Pricing 150

Drug Pricing Biosimilars Vaccines Drug Development 150

STAT

NOVEMBER 18, 2024

The positive results from muscle-performance tests come from a small number of patients, but after consulting with the Food and Drug Administration, Regenxbio has expanded its current clinical trial so that it can support the submission of an accelerated approval application in 2026.

Drug Development 292

Drug Development 292

STAT

MARCH 24, 2025

The dawn of a new risk adjustment era Within the next two weeks, the Trump administration will roll out the final Medicare Advantage policies and payments rates for 2026. You know what to do: Send her all of your tips, gossip, and random musings at tara.bannow@statnews.com.

Drug Development 177

Drug Development Hospitals 177

FDA Law Blog: Biosimilars

OCTOBER 13, 2024

No rare pediatric disease vouchers could be awarded even to designated applications after September 30, 2026. It is extremely difficult, if not impossible, to do the long-term planning and substantial fundraising required for drug development without knowing whether such an important and valuable incentive will be there.

Documentation 64

Documentation Drug Development 64

FDA Law Blog: Biosimilars

DECEMBER 23, 2024

This means that, at the current moment, FDA cannot award any priority review vouchers for rare pediatric disease product applications unless it is for a drug that was designated as a drug for a rare pediatric disease not later than December 20, 2024, and such application is approved not later than September 30, 2026.

Drug Development 59

Drug Development 59

FDA Law Blog: Biosimilars

FEBRUARY 11, 2025

However, as we suggested in a recent blog post , the statute did not actually provide any limitations on FDAs authority to grant rare pediatric disease designations , only its authority to grant vouchers.

Drug Development 59

Drug Development 59

STAT

DECEMBER 10, 2024

  Democrats floated the idea of extending the subsidies through 2026 in a year-end deal, and paying for it with a budgetary maneuver that would theoretically extend budget cuts that haven’t actually been implemented, as my colleague Rachel Cohrs Zhang reported. million people would lose coverage annually without the tax credits. 

Drug Pricing 274

Drug Pricing Drug Development Vaccines 274